BUZZ-Aurinia Pharmaceuticals Inc: Rises on positive study results

Thu Sep 29, 2016 6:32pm EDT
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

** Canadian drug developer's U.S.-listed shares up 14 pct at $3.01 after market

** Company says investigational drug Voclosporin achieved primary and all pre-specified secondary endpoints in its phase IIb AURA-LV study for lupus nephritis

** Lupus nephritis is a serious condition that involves inflammation of the kidney

** Up to Thursday's close, stock had risen about 7 pct this year